關(guān)鍵詞： 阿斯利康 Alchemia
2013年4月23日訊 /生物谷BIOON/ --Alchemia公司今天宣布,，已與阿斯利康（AstraZeneca）達(dá)成了一項多靶標(biāo)藥物發(fā)現(xiàn)合作協(xié)議,，所涉及的疾病橫跨多個領(lǐng)域,，包括腫瘤,、呼吸、心血管,、代謝,、感染及神經(jīng)科學(xué)。
該項合作中,，Alchemia將利用專有的多樣性掃描陣列（DSA）和相關(guān)的穩(wěn)定模板多功能裝配（VAST）化學(xué)平臺,，來發(fā)現(xiàn)及開發(fā)針對阿斯利康所提供多個靶標(biāo)的新穎小分子。
根據(jù)協(xié)議條款,，Alchemia將獲得一筆未披露金額的預(yù)付款,，同時將有資格獲得高達(dá)2.4億的里程碑款項及所合作產(chǎn)品在未來銷售的特許權(quán)使用費(fèi)。（生物谷bioon.com）
英文原文：
Brisbane, Australia 23 April 2013 – Alchemia Limited (ASX:ACL), a drug discovery and development company, today announces that it has signed a multi-target, drug discovery collaboration with AstraZeneca AB (AstraZeneca).
This collaboration includes the use of the proprietary Diversity Scanning Array (DSA) and associated Versatile Assembly on Stable Templates (VAST) chemistry platform to discover and develop novel small molecules against multiple AstraZeneca targets. Alchemia will provide VAST chemistry expertise to develop small molecule clinical candidates for AstraZeneca. By accessing Alchemia’sVAST discovery platform, AstraZeneca will seek novel small molecules to treat diseases across a variety of therapeutic areas including oncology, respiratory, cardiovascular, metabolism, infection and neuroscience.
“We are excited to work alongside AstraZeneca’s teams to explore the applications of our proprietary VAST technology against a range of targets,” said Dr. Wim Meutermans, VP of Discovery at Alchemia and co-inventor of the VAST platform.“This collaboration has the potential to demonstrate the unique capabilities and value of VAST and is a pivotal step in the commercialization of both the DSA and the VAST platform. I look forward to developing a strong and productive alliance with AstraZeneca over the coming years.”
“Alchemia’s DSA library and expertise in carbohydrate chemistry are welcome additions to our small molecule corporate collection and early discovery hit finding activities,” said Mike Snowden, Head of Discovery Sciences at AstraZeneca. “We are looking forward to working with Alchemia to maximise the potential of this novel platform in early phase drug discovery at AstraZeneca.”Under the terms of this Agreement, Alchemia will receive an undisclosed upfront payment and iseligible for potential preclinical, clinical and commercial launch payments totalling up to $240M, as well as a single digit royalty
(責(zé)任編輯：yan.mao)
